SOURCE: HealthSonix, Inc.

October 31, 2007 08:30 ET

HealthSonix Announces Expansion in Florida

IRVINE, CA--(Marketwire - October 31, 2007) - HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) today announced that it is has selected a prestigious medical center in Boca Raton, Florida, for the first location of its specialty Arthritis Treatment Centers of America [ATCA]. The grand opening is scheduled for the spring of 2008.

The Arthritis Treatment Centers utilize the most advanced, non-invasive medical technologies and combine them with the best of the established therapies to reduce and even eliminate arthritis pain and restore joint mobility. The current treatment programs have exceptional success rates: 4 out of 5 patients report significant pain reduction in addition to greater mobility, more energy, and improved sleep.

ATCA follows the guidelines published by the American College of Rheumatology which recommend the use of nonpharmacologic therapies as a first line of defense. ATCA practices an integrated approach to arthritis care and the Centers are staffed with healthcare professionals from many of the medical disciplines required to address arthritis: Physical and Occupational Therapy; Rheumatology Rehabilitation; Kinesiology; Psychology; and Nutrition.

"In our facilities we promote wellness through a warm and welcoming environment. Our patients have helped us design many of the amenities that make each visit a pleasant and rewarding experience," stated Dieter D. Doederlein, Vice President of Corporate Development at HealthSonix. "With this new state of the art facility we'll be able to effectively service patients in the Palm Beach County. The new center will also double as a showcase facility and a training center for the South East United States. Arthritis is a number one source of pain in the world and population profile in South East Florida fits with the type of demographics we target with our treatments," added Doederlein.

HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) is a publicly traded medical technology company, engaged in the development, manufacture, and sale of proprietary medical products and biotechnologies that provide pain relief and muscle stimulation for people with osteoarthritis, rheumatoid arthritis, fibromyalgia, and musculoskeletal conditions related to muscle injuries -- essentially medical conditions where acute and chronic pain, muscle stiffness, poor circulation, and diminishing flexibility are among the underlying symptoms. The company's integrated portfolio of Food and Drug Administration ("FDA") registered products currently in the commercial marketplace includes: enSonix@home; AquaSonix Therapy; enSonixPro; and ZingiberRx pain relieving cream.

More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: or by calling the company at 1-877-622-2121.

Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.

Contact Information